A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment
Abstract
BACKGROUND: Drug-induced liver injury (DILI) management during tuberculous meningitis treatment may result in premature rifampicin and isoniazid withdrawal and contribute to poor outcomes.
METHODS: Adults with tuberculous meningitis, enroled into the ACT HIV (N=520) and LAST ACT (N=720) corticosteroid trials (NCT03092817;NCT03100786), who developed DILI were randomised to strategy-1: continue all drugs, unless ALT ≥10x upper limit of normal [ULN], bilirubin ≥43µmol/L, or symptoms worsen; or strategy-2: stop pyrazinamide, unless ALT ≥5x ULN by day 6, bilirubin ≥43µmol/L, or symptoms worsen; or strategy-3: stop rifampicin, isoniazid, pyrazinamide, continue ethambutol, add levofloxacin and aminoglycoside. The primary outcome was the proportion of time, 60-days following DILI randomisation, during which neither rifampicin nor isoniazid were given (or the participant died). Secondary outcomes included acute liver failure, and death/new neurological events.
RESULTS: Sixty-seven participants with DILI were randomised to strategy-1 (n=21), 2 (n=21), and 3 (n=25). Participants had fewer days without rifampicin and isoniazid in strategy-1 (median 7 days [1st-3rd quartile 0-31]) and 2 (9 days [0-21]) than strategy-3 (18 days [11-35]; p=0.022 and p=0.041). No participants developed liver failure. Strategy failure (requiring strategy-3 switch) occurred in 8/21 (38.1%) strategy-1 and 13/21 (61.9%) strategy-2. New neurological event or death after DILI randomisation, until 12 months from…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 720 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.